New MAA with revised entry criteria released by NICE
TreatSMA response to the latest release of the MAA released by NICE today
Biogen Announces New NURTURE Data
At the CureSMA conference this year Biogen on 1st July 2019 published new results from the NURTURE study.
Scotland can now access nusinersen (Spinraza®️) for types 2 and 3
Following recent communication from the Scottish Government, the Scottish Medicines Consortium have now provided guidance that, as well as being available for those with SMA Type 1, from July 2019 nusinersen can be prescribed for those with SMA Types 2 and 3.
Support grows for Spinraza
TreatSMA continues to work with NICE, NHSE and Biogen. We are seeking to expand inclusion if possible based on the recent appeal and campaign that TreatSMA and the community colaborated on together. TreatSMA and the community have made ITV News…
The fight goes on
After sending additional information to the stakeholders, we have now proceeded with appealing the proposed nusinersen guidance and the Managed Access Agreement.
The SMA Community and clinicians react to draft NICE guidance
The clinicians and SMA community react to the draft nusinersen guidance
No update yet but please stay tuned
We are trying to find a way out of the MAA criteria, please stay tuned.
NICE refuses to reconsider Spinraza criteria
NICE is refusing to amend the entry criteria for Spinraza treatment. We are fighting on.